
· Our position as a leading EpiPen insulin biosimilar injector pen manufacturer.
· We are local, based in the United States, with stringent drug quality control and monitoring.
· Our scale, facility redundancy, and robust device supply chain mean we can meet 100% of your market demand without any backorders, leveraging multiple FDA-compliant, GMP-certified facilities for both the active drug substance and the 'fill-finish' final step.
· As one of the top insulin pen manufacturers, we understand how to handle the stability requirements of large batches, from formulation through transportation, without risking product degradation.
· Additionally, MayMag excels in injection pen contract manufacturing by maintaining device continuity assurance with in-house 510k auto device pen manufacturing, clean FDA Form 483 records, and zero warning letters.

MayMag Biologics not only excels in manufacturing but also provides injection pen contract manufacturing services. As a trusted 506e insulin pen OEM manufacturer, MayMag is proud to be recognized among the top insulin pen manufacturers in the industry.

Top insulin pen manufacturers, Medical device manufacturers, insulin injectors, Insulin pen OEM manufacturers, Injection pen contract manufacturing, Diabetes delivery device suppliers, Custom auto-injector manufacturers, Biosimilar drug manufacturers
MayMag Biologics, formerly Tirzepatide Pharma, is a 506e USA-based large-scale industrial manufacturer of FDA short-listed generic drugs such as insulin pens, biosimilars, epinephrine pens, sterile injectable drugs, and Oral GLP-1, supplying generic meds to the government. Not a 50b retail pharmacy and does not serve hospitals and clinics.
email us at: cdmo@tirzepatidepharm.com and copy: oraltide@gmail.com Please do not fill out the form
MayMag Biologics-506e for FDA short-list drugs large-volume manufacturing
US-Based Biosimilar Supply Chain Redundancy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.